期刊
CRYSTAL GROWTH & DESIGN
卷 19, 期 7, 页码 3923-3933出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.cgd.9b00335
关键词
-
资金
- Science and Engineering Research Council of A*STAR, Singapore
- A*STAR - A*STAR Research Attachment Programme (ARAP)
- A*STAR - University of Southampton
The use of cocrystallization as a tool to improve the pharmaceutical profile of the low-solubility drug leflunomide, used in the treatment of arthritis, is herein evaluated. Judicious selection of coformers based upon knowledge-based strategy and crystal engineering principles has resulted in new cocrystals with pyrogallol, 3-hydroxybenzoic acid, 2-picolinic acid, and 2-aminopyrimidine. Characterization and structure determination of these systems were performed using Xray diffraction. Crystal structure analysis revealed that the hydrogen bonding in the crystal structures corroborates well with the knowledge-based prediction tool. Physicochemical properties such as thermal behavior, stability, solubility, and dissolution rate of the pharmaceutically acceptable cocrystals were evaluated to assess their impact on the pharmaceutical profile of leflunomide. When compared with their parent compound leflunomide and the physical mixtures, cocrystals were found to exhibit improved physicochemical properties, showing their potential for development of new solid dosage forms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据